Freestone Grove Partners LP Makes New $6.05 Million Investment in Maplight Therapeutics, Inc. $MPLT

Freestone Grove Partners LP bought a new stake in shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 168,912 shares of the company’s stock, valued at approximately $6,054,000. Freestone Grove Partners LP owned approximately 0.40% of Maplight Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in MPLT. Legal & General Group Plc purchased a new position in shares of Maplight Therapeutics during the 2nd quarter valued at $37,000. Strs Ohio bought a new position in Maplight Therapeutics during the fourth quarter valued at approximately $53,000. Bank of New York Mellon Corp boosted its position in shares of Maplight Therapeutics by 10.1% during the 1st quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company’s stock valued at $802,000 after acquiring an additional 3,608 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Maplight Therapeutics in the 4th quarter worth $70,000. Finally, New York State Common Retirement Fund purchased a new position in Maplight Therapeutics in the fourth quarter worth about $93,000.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Stifel Nicolaus lifted their price objective on shares of Maplight Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Lifesci Capital upgraded Maplight Therapeutics to a “strong-buy” rating in a report on Thursday, May 14th. Craig Hallum restated a “buy” rating and issued a $25.00 price target on shares of Maplight Therapeutics in a report on Tuesday, July 28th. UBS Group cut Maplight Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $52.00 to $13.00 in a research note on Monday, August 10th. Finally, HC Wainwright lowered their target price on shares of Maplight Therapeutics from $45.00 to $26.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Four research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.67.

Insider Activity at Maplight Therapeutics

In other news, Director Troy Cox bought 15,620 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was purchased at an average cost of $9.52 per share, with a total value of $148,702.40. Following the acquisition, the director directly owned 15,620 shares in the company, valued at $148,702.40. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider James Woodruff Lillie sold 22,082 shares of Maplight Therapeutics stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $12.54, for a total transaction of $276,908.28. Following the completion of the transaction, the insider directly owned 202,380 shares of the company’s stock, valued at $2,537,845.20. The trade was a 9.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is owned by insiders.

Maplight Therapeutics Stock Up 0.5%

Shares of NASDAQ MPLT opened at $12.60 on Friday. The business’s 50 day moving average price is $23.97 and its 200 day moving average price is $24.09. The firm has a market cap of $584.36 million and a P/E ratio of -0.30. Maplight Therapeutics, Inc. has a 52 week low of $9.10 and a 52 week high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, August 13th. The company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.40) by $0.08. As a group, research analysts expect that Maplight Therapeutics, Inc. will post -5.12 earnings per share for the current year.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.